SCHEMBL8433491

SCHEMBL8433491

COc1cc(N2CCNCC2)c(F)cc1C#N

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.64
HTR6 P50406 4/20 0.47
HTR3E A5X5Y0 3/20 0.47
HTR3B O95264 3/20 0.47
HTR3A P46098 3/20 0.47
HTR3D Q70Z44 3/20 0.47
HTR3C Q8WXA8 3/20 0.47
ADRB1 P08588 1/20 0.47
DRD2 P14416 1/20 0.47
CYP2C19 P33261 1/20 0.47
DRD3 P35462 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
KDM1A O60341 1/20 0.45
HTR7 P34969 2/20 0.43
TGFBR1 P36897 1/20 0.42
ACVR1 Q04771 1/20 0.42
NCF1 P14598 1/20 0.41
HTR2A P28223 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14722332 0.94 ALDH1A1 (0.60) ALDH1A1HTR6HTR3EHTR3BHTR3A
SCHEMBL30918446 0.89 ALDH1A1 (0.57) ALDH1A1HTR6HTR3EHTR3BHTR3A
SCHEMBL29232386 0.89 ALDH1A1 (0.57) ALDH1A1HTR6HTR3EHTR3BHTR3A
SCHEMBL8431903 0.85 ALDH1A1 (0.56) ALDH1A1HTR6KDM1A
SCHEMBL8108206 0.84 HTR3A (0.56) ALDH1A1HTR6HTR3EHTR3BHTR3A
SCHEMBL8295259 0.82 ALDH1A1 (0.75) ALDH1A1DRD2DRD3LMNAMAPT
SCHEMBL30073656 0.82 ALDH1A1 (0.75) ALDH1A1DRD2DRD3LMNAMAPT
SCHEMBL27046957 0.80 HTR3E (0.51) ALDH1A1HTR6HTR3EHTR3BHTR3A
SCHEMBL2766363 0.79 HTR3E (0.54) ALDH1A1HTR6HTR3EHTR3BHTR3A
SCHEMBL13682945 0.78 HTR6 (0.50) ALDH1A1HTR6HTR3EHTR3BHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368449-B2 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION (US) 2008-05-06 US disclosed
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists ADORA2A, ADORA3, ADORA1 ALDH1A1 591/4885HTR6 44/4885HTR3E 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.